Rare BRCA1 haplotypes including 3’UTR SNPs associated with breast cancer risk

Genetic markers identifying women at an increased risk of developing breast cancer exist, yet the majority of inherited risk remains elusive. While numerous BRCA1 coding sequence mutations are associated with breast cancer risk, BRCA1 mutations account for less then 5% of breast cancer risk. Since 3' untranslated region (3'UTR) polymorphisms disrupting microRNA (miRNA) binding can be functional and can act as genetic markers of cancer risk, we tested the hypothesis that such polymorphisms in the 3'UTR of BRCA1 and haplotypes containing these functional polymorphisms may be associated with breast cancer risk. We sequenced the BRCA1 3'UTR from breast cancer patients to identify miRNA disrupting polymorphisms. We further evaluated haplotypes of this region including the identified 3'UTR variants in a large population of controls and breast cancer patients (n=221) with known breast cancer subtypes and ethnicities. We identified three 3'UTR variants in BRCA1 that are polymorphic in breast cancer populations, and haplotype analysis including these variants revealed that breast cancer patients harbor five rare haplotypes not generally found among controls (9.50% for breast cancer chromosomes, 0.11% for control chromosomes, p=0.0001). Three of these rare haplotypes contain the rs8176318 BRCA1 3'UTR functional variant. These haplotypes are not biomarkers for BRCA1 coding mutations, as they are found rarely in BRCA1 mutant breast cancer patients (1/129 patients= 0.78%). These rare BRCA1 haplotypes and 3'UTR SNPs may represent new genetic markers of breast cancer risk.

[1]  D. Livingston,et al.  BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.

[2]  Montserrat Garcia-Closas,et al.  Genetic susceptibility to breast cancer , 2010, Molecular oncology.

[3]  D. Sgroi,et al.  Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features , 2010, Breast Cancer Research.

[4]  N Harbeck,et al.  Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Saunders,et al.  The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T genotype is a possible breast and ovarian cancer risk factor. , 2009, Genetic testing and molecular biomarkers.

[6]  K. Kidd,et al.  Population-specific variation in haplotype composition and heterozygosity at the POLB locus. , 2009, DNA repair.

[7]  K. Kidd,et al.  Global variation in CYP2C8–CYP2C9 functional haplotypes , 2009, The Pharmacogenomics Journal.

[8]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[9]  Debra L Winkeljohn Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[10]  L. Carey,et al.  What is triple-negative breast cancer? , 2008, European journal of cancer.

[11]  F. Slack,et al.  A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. , 2008, Cancer research.

[12]  Lisa A Carey,et al.  Understanding and treating triple-negative breast cancer. , 2008, Oncology.

[13]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Wei Zhang,et al.  Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. , 2008, Carcinogenesis.

[15]  B. O’Roak,et al.  Haplotype evolution of SLITRK1, a candidate gene for Gilles de la Tourette Syndrome , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  J. Benítez,et al.  Haplotype patterns in cancer-related genes with long-range linkage disequilibrium: no evidence of association with breast cancer or positive selection , 2008, European Journal of Human Genetics.

[17]  K. Hemminki,et al.  Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. , 2007, Carcinogenesis.

[18]  Giske Ursin,et al.  Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. , 2006, Cancer research.

[19]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[20]  L. Esserman,et al.  Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. , 2005, JAMA.

[21]  D. Altshuler,et al.  A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. , 2005, Cancer research.

[22]  D. Hunter,et al.  Haplotype analysis of common variants in the BRCA1 gene and risk of sporadic breast cancer , 2004, Breast Cancer Research.

[23]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[24]  Chen-Yang Shen,et al.  Breast Cancer Risk and the DNA Double-Strand Break End-Joining Capacity of Nonhomologous End-Joining Genes Are Affected by BRCA1 , 2004, Cancer Research.

[25]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[26]  Fengzhu Sun,et al.  Haplotype block structure and its applications to association studies: power and study designs. , 2002, American journal of human genetics.

[27]  Marek Kimmel,et al.  Haplotype and linkage disequilibrium architecture for human cancer-associated genes. , 2002, Genome research.

[28]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Xiong,et al.  Haplotypes vs single marker linkage disequilibrium tests: what do we gain? , 2001, European Journal of Human Genetics.

[30]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[31]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[32]  M. King,et al.  Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. , 1998, JAMA.

[33]  D. Clayton,et al.  Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. , 1997, Human molecular genetics.

[34]  J. Gusella,et al.  Use of cyclosporin a in establishing epstein-barr virus-transformed human lymphoblastoid cell lines , 1984, In Vitro.

[35]  K. Hemminki,et al.  Polymorphisms within microRNA-binding sites and risk of sporadic colorectal cancer , 2008 .

[36]  R. Edlich,et al.  Breast cancer and ovarian cancer genetics. , 2005, Journal of long-term effects of medical implants.

[37]  Kei-Hoi Cheung,et al.  ALFRED: an allele frequency database for diverse populations and DNA polymorphisms , 2000, Nucleic Acids Res..

[38]  Gabriele Rosenthal Wenn alles in Scherben fällt , 1987 .